Related Experiment Video
Updated: May 14, 2025

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
Novel Insights into Dietary Bioactive Compounds and Major Depressive Disorders: Evidence from Animal Studies and
Chwan-Li Shen1, Taha Hassan2, Peyton Presto3
1Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, TX, United States; Center of Excellence for Integrative Health, Texas Tech University Health Sciences Center, Lubbock, TX, United States; Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Abstract:
Clinical depression, including major depressive disorder (MDD), is a chronic mental illness characterized by persistent sadness and indifference. Depression is associated with neuroinflammation, oxidative stress, and neuronal apoptosis in the brain, resulting in microglial overactivation, decreased neuronal and glial proliferation, monoamine depletion, structural abnormalities, and aberrant biochemical activity via the hypothalamic-pituitary-adrenal axis. Recent studies have exhibited the role of dietary bioactive compounds in the mitigation of MDD progression. Here, in this narrative review, we reported the effects of commonly consumed bioactive compounds (curcumin, saffron, garlic, resveratrol, omega-3 fatty acids, ginger, blueberry, tea, and creatine) on MDD and MDD-related neuroinflammation and oxidative stress. The evidence reviewed here is almost exclusively from animal studies and strongly suggests that these commonly consumed bioactive compounds have anti-MDD effects as shown in antidepression-like behaviors, such as increased immobility, sucrose preference, and social interaction. On the basis of the literature/studies reviewed, the proposed molecular mechanisms include 1) the reduction of neuroinflammation activation and oxidative stress, 2) the enhancement of anti-inflammatory and antioxidant properties, 3) the reduction of monoamine oxidase-A production, and 4) the elevation of brain-derived neurotropic factor and neurogenesis. In the future, dietary bioactive compounds on clinical randomized controlled trials are warranted to confirm the findings of preclinical efficacies using bioactive compounds in individuals with MDD.
More Related Videos
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
06:55An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
Published on: December 2, 2015
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Depression: Overview